Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Airflow Obstruction Clear all
Terminated Not applicable Interventional

Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT04217746
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD Exacerbation, Airflow Obstruction
Interventions
High Flow Nasal Cannula
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347
View directory record Official record
Conditions
COPD
Interventions
fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
Drug
Lead sponsor
Arthur F Gelb MD
Individual
Eligibility
20 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

NCT01572792
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
179
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency

NCT01347931
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
NIOV System, Standard Oxygen Cannula
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma

NCT01227070
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

NCT01045161
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

NCT00992680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ROX Anastomotic Coupler System (ACS)
Device
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

NCT01044459
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide 200 µg, Aclidinium Bromide 400 µg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Recruiting No phase listed Observational

Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm

NCT07223749
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational

Longitudinal Observational Study of Severe Asthma

NCT01780142
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

NCT00891462
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
104
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational

Effect of Fasting on the Asthma Inflammasome

NCT02471300
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Jul 21, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00706914
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Tucson, Arizona • Fullerton, California • Lakewood, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01437540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Formoterol Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
137
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01355978
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
Interventions
Noninvasive Open Ventilation System
Device
Lead sponsor
Breathe Technologies, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Concord, California • San Diego, California • Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01551888
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium/formoterol 400/12μg, Formoterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction

NCT00871637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic, Occupational Diseases, Tobacco Use Disorder
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

NCT01825122
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nadolol, Placebo
Drug
Lead sponsor
Invion, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Phoenix, Arizona • Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo

NCT01049360
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium 400 μg / Formoterol 12 μg, Aclidinium 400 μg / Formoterol 6 μg, Aclidinium 400 μg, Formoterol 12 μg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Glendale, Arizona • Pheonix, Arizona • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Completed No phase listed Observational

Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

NCT03072849
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Pulmonary function testing, FAM Therapy
Procedure · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 21, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01437397
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
193
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 21, 2026, 10:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Thermal Imaging as a Potential Diagnostic Tool of Nasal Airflow

NCT03233373
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Seek CompactPro thermal imager
Device
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Jul 21, 2026, 10:22 PM EDT